The global cardiovascular devices market is projected to grow from $74.58 billion in 2025 to $157.32 billion by 2035, representing a 7.70% compound annual growth rate from 2026 to 2035, according to a ResearchAndMarkets.com report. Demand is being supported by cardiovascular disease prevalence, aging populations, minimally invasive procedures and innovation in diagnostics, monitoring, electrophysiology and structural heart therapies. Pulsed field ablation (an energy-based heart rhythm treatment) and next-generation transcatheter heart valves are among the technologies highlighted. Medtronic, Abbott, Boston Scientific and Edwards Lifesciences are identified as leading competitors, while artificial intelligence is creating new opportunities in cardiac diagnostics and monitoring. Regulatory reviews, particularly by the U.S. Food and Drug Administration and international authorities, remain a commercialization challenge. Therapeutic and surgical devices accounted for 77.5% of revenue by device type, hospitals were the leading end user, coronary artery disease was the leading application and North America held 45.68% of the global market in 2025.